US Patent Application 20090263423 - Enhancement of an Immune Response by Administration of a Cationic Lipid-DNA Complex (CLDC)
InventorsAssigneeUS Classes424/209.1, Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.)424/184.1, ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)424/226.1, Hepatitis A virus424/227.1, Hepatitis B virus (e.g., hepatitis B surface antigen (HBsAg), pre-S region, hepatitis B core antigen (HBcAg), hepatitis B e-antigen, Dane particle, etc.)424/243.1Staphylococcus (e.g., Staphylococcus aureus, etc.)Attorney, Agent or FirmInternational ClassesA61K 39/145A61K 39/00 A61K 39/29 A61K 39/085 Abstract textThis invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method. |
| ||||||||||||||
